Zetia angioedema labeling update

Schering-Plough/Merck Zetia labeling update includes addition of postmarketing experience section in "Adverse Reactions" section. 1Updated label notes that hypersensitivity reactions, including angioedema and rash, have been reported during ezetimibe's postmarketing experience. Schering submitted a "changes being effected" supplement April 3. The cholesterol agent was approved Oct. 25 (2"The Pink Sheet" Nov. 4, 2002, p. 5)...